Truist raised the firm’s price target on Astrana Health to $59 from $50 and keeps a Buy rating on the shares. The firm’s post-earnings Q/A with the company indicated that 2024 is “trending strong” and that two-thirds of the 2025 growth rates are “already lock in”, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health lowers FY24 EPS view to $1.12-$1.36 from $1.28-$1.52
- Astrana Health reports Q2 EPS 40c, consensus 39c
- Astrana Health price target raised to $60 from $48 at Stifel
- Astrana Health price target raised to $60 from $50 at BTIG
- Astrana Health Announces Major Acquisitions and Earnout Agreement